Sarcopenia Treatment Market Overview
The global sarcopenia treatment market size was valued at $2,577 million in 2020, and is projected to reach $4,704 million by 2030, registering a CAGR of 6.1% from 2021 to 2030. Sarcopenia is defined as the loss of skeletal muscle mass or flesh as a result of aging. Sarcopenia is characterized by a reduction in muscular size, relative weakness, lack of stamina, difficulty mounting stairs, and poor balance. Exercise level, co-morbidities, nutrition, and other factors all influence the rate of muscle loss. Sarcopenia can result in worse quality of life as well as disability. It refers to the loss of muscle mass and strength that occurs as a result of the normal aging process. Symptoms of sarcopenia include decrease in muscle size, weakness, loss of endurance, trouble in climbing stairs and poor balance.
In developing and poor countries, micronutrient-rich food is consumed in low amounts, resulting in malnutrition. Sarcopenia is caused primarily by malnutrition or vitamin D and vitamin B12 deficiency, which is common among vegetarians and the elderly. As a result, there is no recognized treatment for sarcopenia; nevertheless, proper nutrition and dietary supplements can help with the condition. Nutrition keeps energy levels up and preventing accelerated muscle loss during periods of muscle inactivity. Proteins, amino acids, omega 3 acid, creatine, vitamin D and B12, and calcium carbonate are some of the most significant supplements for simply treating sarcopenia.
The global sarcopenia treatment market has been driven by factors such as rise in the incidence of the elderly population and the growing acceptance of vitamins and dietary supplements. For instance, according to the World Health Organization, by 2050, the world’s population aged 60 years and above is expected reach 2 billion from 900 million in 2015. Furthermore, increase in the cases of sarcopenia is further anticipated to propel the growth of the sarcopenia treatment market. Also, the increase in R&D activities for the treatment of sarcopenia is further estimated to boost the growth of the sarcopenia treatment market. On the other hand, the high-cost of protein supplements and lack of awareness are expected to hamper the market growth during the forecast period.
Moreover, increase in malnutrition and vitamin deficiency in developing countries and increasing per capita healthcare expenditure are expected to drive demand for sarcopenia treatment supplements. In addition, rise in cases of malnutrition because of poor nutritional intake will further provide potential opportunities for the growth of the sarcopenia treatment market in the coming years. However, rise in price of protein supplement and the inaccessibility of sarcopenia treatment drugs is expected to further challenge the growth of the sarcopenia treatment market in the near future.
The impact of COVID-19 pandemic is expected to remain positive for the sarcopenia treatment market. As sarcopenia patients are more vulnerable to COVID-19 infection, which cause systematic inflammation that results into loss of skeletal muscle. Furthermore, in older persons, the need for social isolation during the COVID-19 pandemic has led to protein deficiency and decrease in daily physical activity, which accelerates the loss of muscle strength and function. Persons with diagnosed COVID-19 are also expected to have 2 or 3 weeks of decreased physical functions resulting in secondary sarcopenia. This led to increase in demand for protein supplements that promotes the muscle growth and increases muscle strength. In addition, people who are physically isolated should be given recommendations to do daily exercises such as the ViviFrail graded exercise set, which is primary treatment for sarcopenia. Thus, such factors have impacted the market growth positively in COVID-19.
Sarcopenia Treatment Market Segmentation
The global sarcopenia treatment market is classified on the basis of treatment, route of administration, distribution channel, and region. By treatment, the market is divided into vitamin B12 supplement, Vitamin D & Calcium supplement, protein supplements and others. By route of administration, the market is segmented into oral, parenteral, and enteral. The oral segment is further segmented into hospital pharmacies, drug stores & retail pharmacies and online pharmacies. The parenteral segment is further segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. The enteral segment is further segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. By distribution channel, it is categorized hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. By region, the market is analyzed across, North America, Europe, Asia-Pacific and LAMEA.
Treatment segment review
By treatment, the protein supplements segment was the major revenue contributor, and is projected to grow significantly during the forecast period, owing to increase in the prevalence of malnutrition deficiency across the globe.
By Treatment
Protien Supplements segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.
Route of administration segment review
Based on route of administration, the oral segment was the major revenue contributor, and is projected to grow significantly during the forecast period, owing to increase in number of people suffering from chronic conditions such as cancer and diabetes coupled with rise in geriatric population base, is expected to drive the market during the forecast timeframe.
By Route Of Administration
Oral Segment hold the dominant position and would continue to maintain the lead over the forecast period.
Distribution Channel segment review
Based on distribution channel, the hospital pharmacies segment was the major revenue contributor, and is projected to grow significantly during the forecast period, due to a huge customer base, increase in healthcare expenditure, rise in disease incidence, and the presence of supportive regulatory systems are the key factors anticipating the growth of the market.
By Distribution Channel
Hospital Pharmacies segements holds a dominant position in 2020 and continue to maintain lead in the forecast year
Region segment review
By region, Asia-Pacific accounted for the largest share in 2020, and is anticipated to maintain its dominance from 2020 to 2030, due to high expenditure on R&D, presence of major players & their product availability, and well-established healthcare infrastructure in the region.
The key market players profiled in the sarcopenia treatment market include Abbott laboratories, Inc., American Way (Amway) Corporation, Bayer AG, GlaxoSmithKline plc., Nestle S.A., Pfizer, Inc. Novartis AG, Sanofi, Inc., Zydus Cadila, Ltd. and F-Hoffmann La-Roche.
By Region
Asia Pacific region holds the dominant position in 2020 and would exhibit the highest CAGR of 7.5% during 2021-2030
Key Benefits For Stakeholders
- The study provides an in-depth analysis of the sterilization services market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers sarcopenia treatment market analysis from 2020 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
- A comprehensive analysis of four regions is provided to determine the prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global sarcopenia treatment market growth.
Key Market Segments
By Treatment
- Protein Supplements
- Vitamin B12 Supplements
- Vitamin D & Calcium Supplements
- Others
By Route of Administration
- Oral
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
- Parenteral
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
- Enteral
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
Key Market Players
- Abbott laboratories, Inc.
- American Way (Amway) Corporation
- Bayer AG
- GlaxoSmithKline plc.
- Nestle S.A.
- Pfizer, Inc.
- Novartis AG
- Sanofi, Inc.
- Zydus Cadila, Ltd
- F-Hoffmann La-Roche
Sarcopenia Treatment Market Report Highlights
| Aspects | Details |
 By TREATMENT |
|
 By ROUTE OF ADMINISTRATION |
|
 By DISTRIBUTION CHANNEL |
|
 By Region |
|
 Key Market Players | Zydus Cadilla, Ltd, F. HOFFMANN-LA ROCHE LTD., PFIZER INC., ABBOTT LABORATORIES, INC, NESTLÉ S.A., GlaxoSmithKline plc, Bayer AG, SANOFI INC., Novartis AG, American Way (Amway)Corporation |
Analyst Review
sarcopenia is a disease that cause loss of skeletal muscle mass or flesh in population of all age group but mostly in geriatric population. Sarcopenia is characterized by a reduction in muscular size, relative weakness, lack of stamina, difficulty mounting stairs, and poor balance.
Factors such as rise in awareness regarding sarcopenia disease by government and non-government organizations are boosting the growth of the global sarcopenia treatment market. Moreover, key pharmaceutical players are focusing on new therapies to prevent or improve the symptoms of sarcopenia disease and various other key players in the global sarcopenia treatment market are heavily investing in development of novel drugs is anticipated to boost the market for during the forecast period. However, high-cost of protein supplements and lack of awareness are likely to hamper the market growth during the forecast period.
The total market value of Sarcopenia Treatment Market is $4,704 Million in 2030
The forecast period in the report is from 2021 to 2030
The market value of Sarcopenia Treatment in 2020 was $ 2,577 Million in 2030
The base year for the report is 2020
Yes, Sarcopenia Treatment Market companies are profiled in the report
The top companies that hold the market share in Sarcopenia Treatment Market are are Abbott laboratories, Inc., American Way (Amway) Corporation, Bayer AG, GlaxoSmithKline plc, Nestle S.A.
No, there is no value chain analysis provided in the Sarcopenia Treatment Market report
The key trends in the Sarcopenia Treatment Market are increase in number of patients suffering from osteoarthritis, osteoporosis, and rheumatoid arthritis and increase in demand protein sipplements for treatment
Loading Table Of Content...
